Danish education registers
Proper storage of semaglutide is essential to ensure its effectiveness and safety
Additionally, the ongoing shortages of branded drugs made patients to shift towards compounding pharmacies providing their own version of drugs which made the government to impose compounding restrictions on GLP-1 receptor agonists (GLP-1 RA) owing to the lack of regulatory supervision of compounded versions and rising safety concerns for preventing serious adverse events and hospitalization of patients
Biopharma companies face: Massive competition and potential market saturation with over 500 GLP-1-related clinical trials across 100+ indications Downward price pressure Highly restricted reimbursement and resistance to new indications Mechanism-based stratification can: Enrich clinical trials for responders (response biomarkers) Identify strong responder subgroups (complementary diagnostic) Differentiate competing assets Support development in new indications (biomarker-led indication switching) De-risk late-stage programs (clinical trial design) Previous efforts to expand GLP-1s into new indications - such as the semaglutide Alzheimers trial - largely targeted broad patient groups defined by their clinical symptoms or diagnostic labels
Investors had been hoping that positive findings on CagriSema might help Novo to bounce back quickly
Common side effects include nausea, facial flushing, fatigue, and appetite suppression, particularly during initial dosing [6]
